Junkichi Izumi
Showa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Junkichi Izumi.
Journal of Neurochemistry | 2008
Junkichi Izumi; Masataka Washizuka; Naoyoshi Miura; Yoshihiro Hiraga; Yugo Ikeda
Abstract: We investigated changes in the extracellular levels of acetylcholine (ACh) following local application of serotonergic agents to the dorsal hippocampus of freely moving rats by means of perfusion using a microdialysis technique. Perfusion of serotonin (5‐HT; 10 μM, for 30 min at a rate of 3 μl/min), dissolved in Ringers solution containing 10 μM eserine, showed no marked effect on the extracellular levels of ACh. 8‐Hydroxy‐2‐(di‐n‐propylamino)tetralin (8‐OH‐DPAT; 20 μM), a 5‐HT1A agonist, increased ACh levels, whereas 7‐trifluoromethyl‐4‐(4‐methyl‐1 ‐piperazinyl)‐pymoto[1,2‐a]quinoxaline (CGS‐12066B; 100 μM), a 5‐HT1B agonist, decreased it. Clomipramine (2 μM), an uptake inhibitor of 5‐HT, had no effect on ACh levels. Following perfusion of 1‐(2‐methoxyphenyl)‐4‐[4‐ (2‐phthalimido)butyl]piperazine (NAN‐190; 10 μM), which is a selective 5‐HT1A antagonist, the effect of 8‐OH‐DPAT was totally abolished, whereas CGS‐12066B decreased extracellular ACh levels. 5‐HT, as well as Clomipramine, had a decreasing effect on ACh levels after pretreatment with NAN‐190. These results indicate that the 5‐HT1A receptor, which exists in the dorsal hippocampus, enhances the spontaneous ACh release, and that the mechanism of serotonergic modulation of ACh release partly depends on both the stimulatory control via the 5‐HT1A receptor and the suppressive one via the 5‐HT1B receptor in the dorsal hippocampus of rats.
Pharmacology, Biochemistry and Behavior | 1997
Junkichi Izumi; Masataka Washizuka; Yu Hayashi-Kuwabara; Koji Yoshinaga; Yoshiaki Tanaka; Yugo Ikeda; Yuji Kiuchi; Katsuji Oguchi
We investigated the behavioral changes induced by mild stress in animals that may be relatively susceptible to a depressive-like state, the Fischer 344 rat strain. The mild stress of repeated handling and intraperitoneal (i.p.) injections with saline (2 ml/kg, twice a day for 14 days) elicited a moderate suppression of body weight gain, a decrease in open field activity, and a prolonged immobility during the tail suspension test in Fischer 344 rats compared with Sprague-Dawley rats. Chronic treatment of Fischer 344 rats with imipramine (10 mg/kg i.p., twice a day for 14 days) effectively suppressed open field activity and prolonged immobility. These results suggest that repeated saline injections may be a mild stressor in these rats. In the Fischer 344 strain, which may be vulnerable to the effects of mild stressors, repeated saline injections might induce a depressive-like state and could presumably represent an experimental model for depression.
Behavioural Brain Research | 1997
Naoki Nakata; Hiroshi Suda; Junkichi Izumi; Yoshiaki Tanaka; Yugo Ikeda; Hiroyuki Kato; Yasuto Itoyama; Kyuya Kogure
To clarify the serotonergic mechanisms involved in the protection against ischemic neuronal damage, ZD-211 (citalopram HBr), a serotonin (5-hydroxytryptamine; 5-HT) re-uptake inhibitor, or buspirone, a 5-HT1A agonist, was locally administered into the hippocampus of gerbils. Additionally, to clarify the role of the 5-HT nervous system in the hippocampus during ischemic neuronal damage, animals were subjected to the local administration of 5,7-dihydroxytryptamine (5,7-DHT), a 5-HT neurotoxin, before ischemia challenge. Gerbils received intrahippocampal administration of ZD-211 (200 nmol/animal) or buspirone (20 nmol/animal) before 5-min ischemia. 5,7-DHT was intrahippocampally administered 7 days before a 2-min non-lethal ischemia challenge. In vehicle-treated animals subjected to 5 min of ischemia, almost all hippocampal CA1 pyramidal neurons were lost. The treatment with ZD-211 or buspirone showed a significant protective effect, and the number of neurons was significantly increased compared to vehicle-treated animals. Pretreatment with NAN-190, a 5-HT1A antagonist, completely abolished the protective effect of ZD-211 or buspirone. In the 5,7-DHT-treated animals, the number of neurons was significantly reduced following 2 min of ischemia compared to vehicle-treated animals in which this period of ischemia is non-lethal. Thus, intrahippocampal treatment with ZD-211 or buspirone can protect neuronal damage following transient ischemia in gerbils. These effects of ZD-211 and buspirone were mediated through the 5-HT1A receptor in the hippocampus. Furthermore, the destruction of the 5-HT nervous system in the hippocampus aggravated ischemic neuronal damage. Therefore, this study showed that the enhanced activity of the 5-HT nervous system in the hippocampus may protect against neuronal damage following cerebral ischemia.
Life Sciences | 1996
Junkichi Izumi; Masataka Washizuka; Yu Hayashi-Kuwabara; Koji Yoshinaga; Yoshiaki Tanaka; Yugo Ikeda; Yuji Kiuchi; Katsuji Oguchi
We investigated the behavioral and neurochemical features of Fischer 344 strain rats in which a depressive state was induced by repeated handling and saline injections as a mild stressor. The repeated intraperitoneal injections of saline (2 ml/kg, twice a day for 14 days) elicited a moderate suppression of body weight gain, a decrease in their open field activity and a prolonged immobility in the tail suspension test. In the stress-exposed rats, the tissue content of norepinephrine (NE) was increased in the cerebral cortex and hypothalamus, whereas that of dopamine or serotonin was not affected. Although the stress exposure did not affect the binding properties of either the alpha-1 or beta adrenoceptors, it suppressed cAMP formation stimulated by NE, but not by isoproterenol or forskolin, in the cerebral cortical slices. In the presence of prazosin or phorbol ester, the difference in NE-stimulated cAMP formation between the control and the stress groups was totally abolished. Phenylephrine enhanced isoproterenol-stimulated cAMP formation in the control but not in the stress group. From these results, it is postulated that the alpha-1 potentiation of beta adrenoceptor- stimulated cAMP formation was attenuated in the stress group. These findings suggest that the manipulation of mild stressor with repeated handling and saline injections to Fischer 344 rats elicits a depressive state characterized by the behavioral changes and the attenuated alpha-1 potentiation in the cerebral cortex, and that this manipulation might be available for the study of the stress-induced depressive state as a generally acceptable mild stress model.
Neuropharmacology | 1993
Manabu Matsumoto; Masahiro Inagaki; Yuji Kiuchi; Junkichi Izumi; Yukako Yamazaki; Katsuji Oguchi
We have previously reported a transient and remarkable increase in dopamine (DA) release in the rat striatum during application of 2 mM sodium cyanide (NaCN) through a brain microdialysis membrane. In the present study we examined the involvement of extracellular Ca2+ in this response. Rats were divided into 4 groups. In the NaCN group a microdialysis probe inserted into the striatum was perfused with Ringers solution containing 2 mM NaCN for 60 min. The Ca2+ free + NaCN group was subjected to perfusion with NaCN dissolved in Ca2+ free Ringers solution, and the CdCl2 + NaCN group with the same plus 0.3 mM CdCl2 (a non-specific Ca2+ channel blocker). In the NaCN and Ca2+ free + NaCN groups DA levels in the dialysates increased to 36- and 44-fold of the control level, respectively, while this was suppressed to only a 16-fold increase in the CdCl2 + NaCN group. In response to a 100 mM KCl perfusion given 3 hr later DA levels were increased (22-fold) in the control group. On the other hand this response was inhibited in the NaCN group (3-fold), but not in the other two groups. An in vitro study with striatal slices showed a gradual increase in intracellular Ca2+ during incubation with 2 mM NaCN. These results suggest that excessive influx of extracellular Ca2+ during NaCN perfusion may contribute partly to the increase in the extracellular DA level in the striatum, and also to the suppression of a DA increase in response to high K+ stimulation observed 3 hr later.
Neuroscience Letters | 1992
Yuji Kiuchi; Masahiro Inagaki; Junkichi Izumi; Manabu Matsumoto; Yukako Yamazaki; Katsuji Oguchi
To investigate in vivo effects of energy failure on functions of dopaminergic neurons, we administered 0 (control), 0.2, 1 or 2 mM sodium cyanide (NaCN) dissolved in Ringers solution for 60 min into the rat striatum through a brain microdialysis membrane. During NaCN perfusion, a transient and concentration-dependent increase in dopamine (DA) levels in the dialysate was observed. The maximum DA level during 2 mM NaCN perfusion was found to be 63-fold higher than the control levels. Leves of 3,4-dihydroxyphenylacetic acid and homovanillic acid were continuously lowered during and after NaCN perfusion. These data suggest that suppression of ATP production by NaCN induces an abrupt and remarkable increase in dopamine release from the nerve terminal in the striatum.
Behavioural Brain Research | 1997
Junkichi Izumi; Masataka Washizuka; Yu Hayashi-Kuwabara; Koji Yoshinaga; Yoshiaki Tanaka; Yugo Ikeda; Yuji Kiuchi; Katsuji Oguchi
We investigated the effects of citalopram, a selective serotonin reuptake inhibitor (SSRI), using an animal model for a depressive state. In Fischer 344 rats, known as emotional animals, repeated stress by twice-daily intraperitoneal (i.p.) saline injections for 14 days elicited a depressive state characterized by a decreased open-field activity and a prolonged immobility during the tail-suspension test. Concomitantly, suppression of norepinephrine (NE)-induced cAMP formation was found in the cerebral cortical slices of the stress-exposed rats without changes in adrenergic alpha 1- or beta-receptors. The difference in cAMP formation between the intact and the stress groups was totally abolished under the blockade of the alpha 1-receptor system or by the stimulation with isoproterenol or forskolin, whereas the suppressed response in the stress group was also observed in combination with isoproterenol and phenylephrine. From these results, we confirmed that the potentiation of the beta-receptor-stimulated cAMP formation by the alpha 1-receptor is attenuated following repeated stress. Chronic i.p. administration of citalopram dissolved in saline improved both the suppressed open-field activity and the prolonged immobility in the tail-suspension test. The animals treated with citalopram exhibited a comparable alpha 1-potentiation effect as observed in the intact rats. However, another SSRI, paroxetine, was less effective on the attenuation of the alpha 1-potentiation in spite of its behavioral improvement in the depressive state. These findings suggest that citalopram has a protective effect against the repeated stress-induced depressive state by mechanisms besides the serotonin reuptake inhibition.
Comparative Biochemistry and Physiology B | 1993
Daichi Morioka; Y. Kanda; Junkichi Izumi; Miyuki Hashimoto; Masahiro Inagaki; Yuji Kiuchi; Katsuji Oguchi
1. Enzyme properties of monoamine oxidase (MAO) in the frontal cortex and liver of the gerbil were investigated using 5-hydroxytryptamine (5-HT), benzylamine (Bz) and tyramine (Tyr) as substrates. 2. The Km values of MAO towards the three substrates were almost similar to the values in other species. The Vmax value of MAO towards Bz was much lower than the value towards 5-HT. 3. In the inhibition studies with selective MAO-A and MAO-B inhibitors, clorgyline and deprenyl, deamination of 5-HT, Bz and Tyr in both tissues was induced by MAO-A alone, MAO-B alone and both forms of the enzyme, respectively, indicating the same substrate specificity as that in rats. 4. The apparent proportion of MAO-A to MAO-B activities in the gerbil liver was approximately 6:4, whereas MAO-A in the frontal cortex of the gerbil was exclusively predominant, consistent with the previous data in the golden hamster which belongs to the same family as the gerbil.
Japanese Journal of Pharmacology | 1993
Junkichi Izumi; Masahiro Inagaki; Yuji Kiuchi; Manabu Matsumoto; Yukako Yamazaki; Daichi Morioka; Shino Usami; Katsuji Oguchi
Folia Pharmacologica Japonica | 1995
Toshihiro Matsumura; Hiroyasu Furuichi; Junkichi Izumi; Hiroshi Suda; Shigeru Ito; Mineo Takei; Naoki Nishi; Tadashi Mori; Yoshiaki Tanaka; Tadashi Kurimoto